These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 38627025)
1. Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer. Laukhtina E; Gontero P; Babjuk M; Moschini M; Teoh JY; Rouprêt M; Trinh QD; Chlosta P; Nyirády P; Abufaraj M; Soria F; Klemm J; Bekku K; Matsukawa A; Shariat SF BJU Int; 2024 Oct; 134(4):644-651. PubMed ID: 38627025 [TBL] [Abstract][Full Text] [Related]
2. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer. Liu K; Zhao H; Chen X; Nicoletti R; Vasdev N; Chiu PK; Ng CF; Kawada T; Laukhtina E; Mori K; Yanagisawa T; D'Andrea D; von Deimling M; Albisinni S; Krajewski W; Pradere B; Soria F; Moschini M; Enikeev D; Shariat S; Kamat A; Giannarini G; Teoh JY; Eur Urol Oncol; 2024 Jun; 7(3):438-446. PubMed ID: 37827948 [TBL] [Abstract][Full Text] [Related]
3. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476 [TBL] [Abstract][Full Text] [Related]
4. Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis. Yanagisawa T; Quhal F; Kawada T; Mostafaei H; Motlagh RS; Laukhtina E; Rajwa P; von Deimling M; Bianchi A; Pallauf M; Majdoub M; Pradere B; Abufaraj M; Moschini M; Karakiewicz PI; Iwatani K; Miki J; Kimura T; Shariat SF BJU Int; 2023 Jun; 131(6):643-659. PubMed ID: 36479820 [TBL] [Abstract][Full Text] [Related]
5. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466 [TBL] [Abstract][Full Text] [Related]
6. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer. Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307 [TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer. Tan X; Liu Z; Cai T; Wang Y; Wu Z; Qin Z; Li Z; Liu Z; Yuan G; Zhou Q; Yao K Eur Urol Oncol; 2024 Aug; 7(4):760-769. PubMed ID: 37884420 [TBL] [Abstract][Full Text] [Related]
8. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer. Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637 [TBL] [Abstract][Full Text] [Related]
9. Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy. Fujita N; Hatakeyama S; Okita K; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C Urol Oncol; 2021 Mar; 39(3):191.e9-191.e16. PubMed ID: 32713622 [TBL] [Abstract][Full Text] [Related]
10. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843 [TBL] [Abstract][Full Text] [Related]
11. [Intravesical instillation of bacillus Calmette-Guerin for non-muscle invasive bladder cancer: outcomes of 421 patients in a single center]. Cai T; Lu J; Lin Z; Lup M; Liang H; Qin Z; Ye Y Nan Fang Yi Ke Da Xue Xue Bao; 2023 Mar; 43(3):488-494. PubMed ID: 37087596 [TBL] [Abstract][Full Text] [Related]
12. Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis. Pazir Y; Esmeray A; Caglar U; Erbin A; Ozgor F; Sarilar O; Akbulut F Int Urol Nephrol; 2024 Mar; 56(3):957-963. PubMed ID: 37880493 [TBL] [Abstract][Full Text] [Related]
14. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor. Huang B; Huang G; Li W; Chen L; Mao X; Chen J J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014 [TBL] [Abstract][Full Text] [Related]
15. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502 [TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study. Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ; Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117 [TBL] [Abstract][Full Text] [Related]
17. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. Shepherd AR; Shepherd E; Brook NR Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259 [TBL] [Abstract][Full Text] [Related]
18. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study. Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E; Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624 [TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer. D'Andrea D; Soria F; Abufaraj M; Pones M; Gontero P; Machado AT; Waksman R; Enikeev DV; Glybochko PV; Adonias SP; Nahas WC; Shariat SF; Chade DC Clin Genitourin Cancer; 2020 Feb; 18(1):20-25.e2. PubMed ID: 31786120 [TBL] [Abstract][Full Text] [Related]
20. [Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder]. Isbarn H; Budäus L; Pichlmeier U; Conrad S; Huland H; Friedrich MG Urologe A; 2008 May; 47(5):608-15. PubMed ID: 18317718 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]